PAREXEL MassBio Lunch & Learn
October 16, 2017
Cambridge, MA (USA)
Monday, October 16, 2017
Registration/lunch starts at 11:00am
Presentation starts at 11:30 am to 1:00 pm
Precision medicine is changing the reality of drug development, patient care and cost-benefit decision making. Genomics, proteomics, metabolomics and other biomarkers are expanding our understanding of disease, improving our ability to identify and develop novel targets, understand variation in patient response, improve patient outcomes and impact likelihood of approval and reimbursement.
Over the next five years, personalized medicines in development are expected to increase to nearly 70%, according to the Tufts Center for the Study of Drug Development. This session will explore how drug developers are adapting their thinking beyond traditional drug development models to leverage genomic information in developing these new medicines.
Topics/Case Studies for discussion:
• Leveraging genomics - from target discovery to pharmacogenomics in development
• Considerations for developing precision medicines beyond oncology
• Market Implications of companion diagnostic decisions
Anita Nelsen, Sr. Director and Head, Genomic Medicine, PAREXEL International
Michelle Penny, Senior Director, Head of Computational Biology and Genomics, Biogen
Charles Paulding, Director Pharmacogenomics, Regeneron Pharmaceuticals, Inc.
Gary Gustavsen, Partner, Precision Medicine, Health Advances